Navigation Links
Red wine vs. white? It makes no difference when it comes to breast-cancer risk
Date:3/8/2009

SEATTLE The largest study of its kind to evaluate the effect of red versus white wine on breast-cancer risk concludes that both are equal offenders when it comes to increasing breast-cancer risk. The results of the study, led by researchers at Fred Hutchinson Cancer Research Center, were published in the March issue of Cancer Epidemiology, Biomarkers and Prevention.

"We were interested in teasing out red wine's effects on breast-cancer risk. There is reason to suspect that red wine might have beneficial effects based on previous studies of heart disease and prostate cancer," said lead author Polly Newcomb, Ph.D., M.P.H., head of the Cancer Prevention Program in the Public Health Sciences Division at the Hutchinson Center. "The general evidence is that alcohol consumption overall increases breast-cancer risk, but the other studies made us wonder whether red wine might in fact have some positive value."

Instead, Newcomb and colleagues found no compelling reason to choose Chianti over Chardonnay.

"We found no difference between red or white wine in relation to breast-cancer risk. Neither appears to have any benefits," Newcomb said. "If a woman drinks, she should do so in moderation no more than one drink a day. And if a woman chooses red wine, she should do so because she likes the taste, not because she thinks it may reduce her risk of breast cancer," she said.

The researchers found that women who consumed 14 or more drinks per week, regardless of the type (wine, liquor or beer), faced a 24 percent increase in breast cancer compared with non-drinkers.

For the study, the researchers interviewed 6,327 women with breast cancer and 7,558 age-matched controls about their frequency of alcohol consumption (red wine, white wine, liquor and beer) and other breast-cancer risk factors, such as age at first pregnancy, family history of breast cancer and postmenopausal hormone use. The study participants, ages 20 to 69, were from Wisconsin, M
'/>"/>

Contact: Kristen Lidke Woodward
kwoodwar@fhcrc.org
206-667-5095
Fred Hutchinson Cancer Research Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. New drug makes weight loss safer
2. How mother of thousands makes plantlets
3. For honey bee queens, multiple mating makes a difference
4. Scientists spy enzyme that makes us unique
5. Thinking makes it so: Science extends reach of prosthetic arms
6. Choosing dry or wet food for cats makes little difference
7. Technique controls nanoparticle size, makes large numbers
8. Decoy makes sitting duck of superbugs
9. Case researcher in RNA biology makes waves by challenging current thinking
10. New process makes nanofibers in complex shapes and unlimited lengths
11. Diabetes makes it hard for blood vessels to relax

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...ousands of years it has been prescribed by traditi...s from headaches and stomach pain to fever and flu...tle University have been able to scientifically pr...ta otherwise known as Brazilian mint. , Testing...m led by researcher Graciela Rocha was able to sho...
(Date:11/24/2009)... that keep weakened and flabby arteries from colla...nths, those stents are no longer needed -- once th...ry. Previously, doctors had no choice but to leave...Aviv University,s Department of Biomedical Enginee...form that carries drugs where they,re needed, then...
(Date:11/24/2009)...N ROUGE Antarctica has long held secrets of the e... recently, there has been very little information ...miles of ice for millions of years. Now, a team of... have been funded to the tune of $10 million doll... get to the bottom of things literally. These sci...
Breaking Biology News(10 mins):Got a pain? -- Have a cup of Brazilian mint 2A coating for life 2LSU gets to the bottom of things -- in Antarctica 2Virtify Inc Delivers Industrys First Enterprise Content Compliance Software Suite for Life Sciences Companies 12722 1Virtify Inc Delivers Industrys First Enterprise Content Compliance Software Suite for Life Sciences Companies 12722 2Virtify Inc Delivers Industrys First Enterprise Content Compliance Software Suite for Life Sciences Companies 12722 3Virtify Inc Delivers Industrys First Enterprise Content Compliance Software Suite for Life Sciences Companies 12722 4Virtify Inc Delivers Industrys First Enterprise Content Compliance Software Suite for Life Sciences Companies 12722 5Iran Blocks Access to the Chopra Center 26apos 3Bs Web Site Podcasts and Blogs 49586 1Iran Blocks Access to the Chopra Center 26apos 3Bs Web Site Podcasts and Blogs 49586 2Iran Blocks Access to the Chopra Center 26apos 3Bs Web Site Podcasts and Blogs 49586 3China Pharma Holdings Inc Announces SFDA Approval for Rosuvastatin Clinical Trials 49581 1China Pharma Holdings Inc Announces SFDA Approval for Rosuvastatin Clinical Trials 49581 2China Pharma Holdings Inc Announces SFDA Approval for Rosuvastatin Clinical Trials 49581 3
...n a mud flat at the edge of the Cocheco River, jus...ersity of New Hampshire,s Contaminated Sediments C...ted sediment in coastal waterways. , Rather than ...al feet of sand, they,ve created a patch black ge...ion in place. Over the next two years, UNH associa...
... is available in German . , Infectious proteins... of "mad cow" disease (BSE). The culprits are "inc...y proteins. The molecular bases for such prion dis...roteins infectious while others are not? A team he...aimon Sabat (University of Bordeaux, France) has e...
...f., June 16 Authernative, Inc., a,leading develop...management,technologies, announced today that it h...n (GSA) Information Technology Schedule contract, ...tive to sell its AuthGuard(R),user authentication ... Schedule contract, which represents Authernative,...
Other Biology News:UNH researchers test sediment-scrubbing technology in NH river 2UNH researchers test sediment-scrubbing technology in NH river 3Tracking prions 2Authernative Awarded GSA Schedule Contract 2Authernative Awarded GSA Schedule Contract 3
(Date:11/24/2009)...w York investment bank KTA Capital,s client Neuren...7 mil convertible note private placement with a U....as arranged by KTA Capital as Neuren,s exclusive p... New York (PRWEB) November 23, 2009 -- The ind... ("KTA Capital") has announced that its ...
(Date:11/24/2009)...re-FirstCall/--Sigma-AldrichCorporation(Nasdaq: SI...day,December1stat1:45PMGMTinLondon,7:45AMUS/CST.In...heInternetavailableat http://inve s tor.sig m ...toaccessthisfile. ,, AboutSigma-Aldrich: Sig...mpany.Itschemicalandbiochemicalproductsandkitsareu...
(Date:11/24/2009)...RNewswire-FirstCall/--NeurogesX,Inc.(Nasdaq: NGSX ...ommercializingnovelpainmanagementtherapies,announc...veOfficer,isscheduledtopresentatthe21stAnnualPiper...09atTheNewYorkPalaceHotelinNewYork,NewYork. ,, ...r,willbeavailabletorespondtoquestionsduringthepres...
(Date:11/24/2009)...asbeenmetforpatientswithadvanced-stage,orrecurrent...wire-FirstCall/-AEternaZentarisInc.(NASDAQ: AEZS ;...panyfocusedonendocrinetherapyandoncology,todayanno...rgetedcytotoxicpeptideconjugate,AEZS-108(formerlyA...lcancer.Inapersonalizedhealthcareapproach,thestudy...
Breaking Biology Technology:KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4
...TON, July 29 Scimitar Equity, LLC issues a review...ard: VOQP), entitled, "510k,Application Submitted ...cta(TM) Focuses Milestones and Share Price Appreci...tp://www.scimitarequity.com ., VioQuest Pharmaceu...,dedicated to becoming a recognized leader in the ...
... CARLOS, Calif., July 29 Nuvelo, Inc.,(Nasdaq: N...st subject in a,single-center, Phase 1 trial of re...lead compound from its Wnt Therapeutics Program. T...ding dose (SAD) trial will,determine the safety, t...ous (IV) administration of NU206, in approximately...
... "As one of AFRA,s fou...ceive its accreditation," remarks Gregoire Le... "For more than 10 years our vision in the gl...n, JMV Aviation and BAR) has been to operate in a ... to our five locations in France as well as facili...
Other Biology Technology:VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC 2Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers 2Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers 3First Program Addressing Aircraft Industry Sustainability Awards Accreditation To Five Global Companies 2First Program Addressing Aircraft Industry Sustainability Awards Accreditation To Five Global Companies 3First Program Addressing Aircraft Industry Sustainability Awards Accreditation To Five Global Companies 4
RDF (R106-05) from European Collection of Cell Cultures (ECACC)
...The Brownlee Precision Model 440 incorporates four...rcuitry in a friendly easy-to-use instrument. Each...er, an 8-pole Bessel lowpass filter, a highpass fi...ols. A control knob sets the amplifier parameters ...
REK (R102-05) from European Collection of Cell Cultures (ECACC)
PCAEC (P300-05) from European Collection of Cell Cultures (ECACC)
Biology Products: